Anaptysbio (ANAB) Revenue Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Revenue Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 16.50% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 296.11% |
| 10 | Anaptysbio | 1.63 Bn | 1.34 Bn | - | -7.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -7.98% |
| Dec 31, 2025 | 200.00% |
| Sep 30, 2025 | 154.26% |
| Jun 30, 2025 | 102.93% |
| Mar 31, 2025 | 286.84% |
| Dec 31, 2024 | 177.62% |
| Sep 30, 2024 | 804.67% |
| Jun 30, 2024 | 217.08% |
| Mar 31, 2024 | 422.49% |
| Dec 31, 2023 | 80.10% |
| Sep 30, 2023 | 156.61% |
| Jun 30, 2023 | 184.54% |
| Mar 31, 2023 | 41.65% |
| Dec 31, 2022 | 394.56% |
| Sep 30, 2022 | -93.81% |
| Jun 30, 2022 | -95.95% |
| Mar 31, 2022 | -91.38% |
| Dec 31, 2021 | -98.32% |
| Mar 31, 2021 | -25.02% |
| Dec 31, 2020 | 1,900.00% |